- $15.32bn
- $14.44bn
- $531.11m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 70.8 | 162 | 251 | 369 | 531 |
Cost of Revenue | |||||
Gross Profit | 50 | 116 | 182 | 270 | 389 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 84.9 | 178 | 311 | 435 | 544 |
Operating Profit | -14.1 | -16 | -60 | -65.2 | -12.8 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.6 | -15.7 | -60 | -58.6 | 17.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.6 | -15.8 | -60.1 | -59.6 | 16.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.6 | -15.8 | -60.1 | -59.6 | 16.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.6 | -15.8 | -60.1 | -59.6 | 16.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.378 | -0.44 | -2.34 | -1.5 | 0.342 |
Dividends per Share |